

1 **Bimodal distribution and set point HBV DNA**
2 **viral loads in chronic infection: retrospective**
3 **analysis of cohorts from the UK and South Africa**

4
5 Louise O Downs^{1,2}, Sabeehah Vawda³, Phillip Armand Bester³,
6 Katrina A Lythgoe^{4,5}, Tingyan Wang², Anna L McNaughton², David A Smith^{2,6,9},
7 Tongai Maponga⁷, Oliver Freeman^{6,11}, Kinga A Várnai^{6,9}, Jim Davies^{6,10},
8 Kerrie Woods^{6,9}, Christophe Fraser⁴, Eleanor Barnes^{2,6,8},
9 Dominique Goedhals³, Philippa C Matthews^{1,2,6}

10
11 ¹ Department of Infectious Diseases and Microbiology, Oxford University Hospitals
12 NHS Foundation Trust, Oxford, UK;

13 ² Nuffield Department of Medicine, Medawar Building for Pathogen Research,
14 University of Oxford, Oxford, UK;

15 ³ Division of Virology, University of the Free State and National Health Laboratory
16 Service, Bloemfontein, South Africa;

17 ⁴ Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield
18 Department of Medicine, University of Oxford, United Kingdom

19 ⁵ Department of Zoology, University of Oxford, M Medawar Building for Pathogen
20 Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK

21 ⁶ National Institute of Health Research Health Informatics Collaborative, NIHR Oxford
22 Biomedical Research Centre, Oxford, UK;

23 ⁷ Department of Virology, University of Stellenbosch, Tygerberg Hospital, Cape
24 Town, South Africa

25 ⁸ Department of Hepatology, Oxford University Hospitals NHS Foundation Trust,
26 Oxford, UK;

27 ⁹ Oxford University Hospitals NHS Foundation Trust, Oxford, UK;

28 ¹⁰ Department of Computer Science, University of Oxford, Oxford, UK;

29 ¹¹ Nuffield Department of Population Health, University of Oxford, Oxford, UK.

30
31
32 **CONFLICT OF INTEREST: Nil**

33
34 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 **CORRESPONDING AUTHOR**

36 **Professor Philippa C Matthews:**

37 **Email:** philippa.matthews@ndm.ox.ac.uk

38 **Address:** Medawar Building for Pathogen Research, South Parks Road,
39 Oxford OX1 3SY, UK

40 **Telephone:** 0044 1865 271973

41

42 **AUTHORS' CONTRIBUTIONS**

- 43 • Study concept and design: PCM, ALM.
- 44 • Development of the health informatics (HIC) pipeline: DS, JD, OF, KV, KW
- 45 • Acquisition and interpretation of South African data: SV, PAB, TM, DG, LOD
- 46 • Acquisition and interpretation of UK data: LOD, DAS, ALM
- 47 • Analysis of the data: TW, CF, KAL
- 48 • Literature review: LOD, PCM
- 49 • Wrote the manuscript: LOD, PCM
- 50 • Critical revision of manuscript: LOD, PCM, ALM, KAL, CF
- 51 • Edited and approved the final manuscript: All authors

52

53

54 **FUNDING**

55 PCM is funded by the Wellcome Trust (ref 110110). KAL is funded by the Wellcome
56 Trust and the The Royal Society (ref 107652/Z/15/Z). LOD is funded by the NIHR.

57

58 Introduction

59 Hepatitis B virus (HBV) DNA viral loads (VL) show wide variation between individuals
60 with chronic hepatitis B (CHB) infection, and are used to determine treatment
61 eligibility (1). There are few refined descriptions of VL distribution in CHB, and limited
62 understanding of the biology that underpins these patterns. We set out to describe
63 the VL distribution in independent cohorts from the UK and South Africa, to identify
64 associated host characteristics, and to compare with VL in HIV-1 and hepatitis C
65 (HCV) infection.

66

67 Methods

68 We retrospectively collected baseline and longitudinal HBV VL measurements,
69 HBeAg status and demographic data from treatment-naïve adults with CHB between
70 2011-2016 from electronic records at a UK teaching hospital (n=351), as described
71 previously (2). We also analysed all HBV VL data from the South African National
72 Health Laboratory Service (NHLS), representing a four-year period from 1st January
73 2015 (n=6506). We used longitudinal data from the UK HBeAg-negative cohort, and
74 from South African patients with detectable viraemia to investigate the relative
75 contributions of within- and between-host variation to VL variability. A large
76 contribution of between-host variation would provide support for a set-point viral load
77 (SPVL), as is observed for HIV. We compared HBV VLs with pre-treatment HCV VLs
78 from the same UK cohort (n=925) and HIV SPVLs from a previous European study
79 (n=1581) (3). More details of clinical cohorts and statistical analysis are presented in
80 Suppl. methods.

81

82 Results

83 In the UK cohort, overall median HBV VL was 3.4 log₁₀ IU/mL; 95% CI 3.2 – 3.5 log₁₀
84 IU/mL (equivalent to median 4.2 log₁₀ copies/ml). There was a bimodal VL
85 distribution (Fig 1A) with peaks as follows:

- 86 • HBeAg-negative infection (accounting for 304/351 (87%) of measurements):
87 median VL 3.2 log₁₀ IU/mL (95% CI 3.0 – 3.4); right-skewed distribution (Fig
88 1A).
- 89 • HBeAg-positive infection (accounting for 47/351 (13%) of measurements):
90 median VL 7.6 log₁₀ IU/mL (95% CI 5.6 – 8.2); left-skewed distribution (Fig
91 1B)

92 In the South African dataset (HBeAg status not determined), median HBV VL was
93 4.6 log₁₀ IU/mL (95% CI 3.9 – 4.0), with a bimodal distribution and right-skew (Fig
94 1C).

95

96 For the UK data we investigated whether sex, age or ethnicity had any influence on
97 VL; the only significant association was lower VL with increasing age in the HBeAg-
98 positive group (p=0.01 by Kruskal Wallis, Suppl. Fig 1).

99

100 Longitudinal data were available for 299 patients in the UK cohort and 874 patients
101 in the South African cohort. Inter-patient variation accounted for 82.7% and 88.0% of
102 the variability in UK and South African datasets respectively, whilst within-patient
103 variation accounted for 17.3% and 12.0%. This provides support for a stable SPVL
104 within individuals with CHB.

105

106 Median HIV VL was 4.5 log₁₀ copies/mL and median HCV VL was 6.0 log₁₀ IU/ml
107 (6.4 log₁₀ copies/ml), with a left skew and no bimodal distribution (Fig 1D,E), and
108 significantly different viraemia compared to HBV (p<0.0001; Fig 1F).

109

110 **Discussion**

111 HBV VL distribution in our diverse UK population is in keeping with a large South
112 African dataset, as well as other previously published studies (e.g. (4–6)). Although
113 the bimodal distribution of HBV VL is consistent between cohorts, descriptions of this
114 pattern have not previously been carefully refined. The relationship between HBeAg
115 status and VL is in keeping with the role of HBeAg in immunomodulation (7).

116

117 HBV viral loads in HBeAg-negative infection are significantly lower than HCV and
118 HIV, which may relate to differences in viral population structure, viral fitness,
119 influence of host immune responses, and the availability of target cells. These
120 factors might also explain why HIV, HCV and HBeAg-positive infection have left
121 skew VL distributions, whereas HBeAg-negative infection has a right skew. This is
122 the first study to explore the concept of SPVL in HBV infection, with between-host
123 factors explaining over 80% of the variation in VL measurements during HBeAg-
124 negative CHB.

125

126 Our data represent a small but well-defined UK cohort, and a much larger South
127 African population without the benefit of relevant supporting metadata; long-term
128 aspirations will be to investigate larger VL datasets together with robust clinical and
129 laboratory parameters.

130

131 Next generation sequencing (NGS) has the potential to increase our understanding
132 of HBV but approximately 50% of cases fall below the current sequencing threshold
133 of $\sim 3 \log_{10}$ IU/mL (8). Enhanced descriptions of HBV VL may shed light on the
134 biology of chronic HBV infection, improve understanding of risk factors for
135 transmission and disease progression at a population level, inform optimisation of
136 viral sequencing methods, and help to stratify patients for clinical trials and
137 treatment.

138

139 **Metadata**

140 The metadata underpinning this analysis are available on-line:

141 <https://figshare.com/s/cd8b046346250dd349b0>

142 On acceptance of this manuscript for publication, the data will be made available
143 through a permanent DOI: 10.6084/m9.figshare.11365082


144

145


146

147 **Figure 1: Distribution of viral loads for adults with chronic infection with HBV,**
 148 **HIV and HCV**
 149


A: HBV (UK cohort): HBeAg-negative




B: HBV (UK cohort): HBeAg-positive




C: HBV (S. Africa cohort)



D: HIV (BEEHIVE cohort)




E: HCV (UK cohort)



F: HBV vs HIV vs HCV

Median, IQR and 5-95% percentiles indicated
 Kruskal Wallis $p < 0.0001$



150
 151

152 | **References**

153

- 154 1. Lampertico P, Agarwal K, Berg T et al. EASL 2017 Clinical Practice Guidelines on the
155 management of hepatitis B virus infection. *J Hepatol*. 2017;**67(2)**:370–98.
- 156 2. Downs LO, Smith DA, Lumley SF et al. Electronic Health Informatics Data To Describe
157 Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in
158 Chronic Hepatitis B Virus Infection. *MBio*. 2019. **25**;10(3).
- 159 3. Blanquart F, Wymant C, Cornelissen M et al. Viral genetic variation accounts for a third of
160 variability in HIV-1 set-point viral load in Europe. *PLoS Biol*. 2017. **15(6)**:e2001855.
- 161 4. Pyne MT, Vest L, Clement J et al. Comparison of three roche hepatitis B virus viral load assay
162 formats. *J Clin Microbiol*. 2012; **50(7)**:2337–42. —
- 163 5. Meldal BHM, Bon AH, Prati D, Ayob Y, Allain JP. Diversity of hepatitis B virus infecting
164 Malaysian candidate blood donors is driven by viral and host factors. *J Viral Hepat*. 2011;
165 **18(2)**:91–101.
- 166 6. Allain JP, Candotti D, Soldan K et al. The risk of hepatitis B virus infection by transfusion in
167 Kumasi, Ghana. *Blood*. 2003. **101(6)**:2419–25.
- 168 7. Milich D, Liang TJ. Exploring the Biological Basis of Hepatitis B e Antigen in Hepatitis B Virus —
169 Infection. *Hepatology*. 2003. **38**:1075–86.
- 170 8. McNaughton AL, D'Arienzo V, Ansari MA et al. Insights From Deep Sequencing of the HBV
171 Genome—Unique, Tiny, and Misunderstood. *Gastroenterology*. 2019;**156(2)**:384–99.

172